Cargando…

Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease

Avatrombopag is an orally-administered small molecule thrombopoietin receptor agonist. It was the third thrombopoietin receptor agonist approved for the treatment of immune thrombocytopenia and the first approved to treat periprocedural thrombocytopenia in patients with chronic liver disease (thereb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheloff, Abraham Z, Al-Samkari, Hanny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733339/ https://www.ncbi.nlm.nih.gov/pubmed/31565009 http://dx.doi.org/10.2147/JBM.S191790

Ejemplares similares

Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features
por: Cheloff, Abraham Z., et al.
Publicado: (2020)

Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study
por: Al‐Samkari, Hanny, et al.
Publicado: (2022)

Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
por: Mladsi, Deirdre, et al.
Publicado: (2020)

Avatrombopag: A Review in Thrombocytopenia
por: Markham, Anthony
Publicado: (2021)

PB2623: AVATROMBOPAG FOR THE TREATMENT OF CHILDREN WITH PERSISTENT AND CHRONIC IMMUNE THROMBOCYTOPENIA
por: An, Qi, et al.
Publicado: (2023)

Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2019)

Correction to: Avatrombopag: A Review in Thrombocytopenia
por: Markham, Anthony
Publicado: (2021)

Thrombotic Complications in Immune Thrombocytopenia Patients Treated with Avatrombopag
por: Abdelsamia, Mahmoud, et al.
Publicado: (2023)

The role of romiplostim for pediatric patients with immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

COVID-19 vaccination and immune thrombocytopenia: Cause for vigilance, but not panic
por: Al-Samkari, Hanny
Publicado: (2023)

PB2637: OUR EXPERIENCE WITH AVATROMBOPAG TREATMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Cervinek, Libor
Publicado: (2023)

Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag
por: Abdela, Jemal
Publicado: (2019)

Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives
por: Tsykunova, Galina, et al.
Publicado: (2022)

Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure
por: Satapathy, Sanjaya K., et al.
Publicado: (2023)

Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation
por: Zhou, Meng, et al.
Publicado: (2022)

Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice
por: Song, Fei, et al.
Publicado: (2021)

Avatrombopag ethnic sensitivity analysis in chronic liver disease and thrombocytopenia patients: individual-level pooled analysis
por: Lu, Jun, et al.
Publicado: (2022)

Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study
por: Oladapo, Abiola, et al.
Publicado: (2023)

Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China
por: Mei, Heng, et al.
Publicado: (2023)

Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments
por: Aiello, Andrea, et al.
Publicado: (2023)

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
por: Jurczak, Wojciech, et al.
Publicado: (2018)

Response to rituximab in children and adults with immune thrombocytopenia (ITP)
por: Harris, Emily M., et al.
Publicado: (2021)

Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges
por: Huang, Ao, et al.
Publicado: (2022)

Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis
por: Wojciechowski, Piotr, et al.
Publicado: (2021)

Clinical efficacy of avatrombopag and recombinant human thrombopoietin in the treatment of chronic liver disease-associated severe thrombocytopenia: A real-world study
por: Wang, Yong-Shuai, et al.
Publicado: (2022)

Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies
por: Poordad, Fred, et al.
Publicado: (2020)

Two elective invasive procedures after a single avatrombopag treatment in a patient with liver cirrhosis and severe thrombocytopenia
por: Biolato, Marco, et al.
Publicado: (2022)

Correction to: Two elective invasive procedures after a single avatrombopag treatment in a patient with liver cirrhosis and severe thrombocytopenia
Publicado: (2022)

The pathophysiology of thrombocytopenia in chronic liver disease
por: Mitchell, Oscar, et al.
Publicado: (2016)

Analysis of the Efficacy and Safety of Avatrombopag Combined With MSCs for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Zhu, Lidan, et al.
Publicado: (2022)

Avatrombopag for the treatment of thrombocytopenia in children's patients following allogeneic hematopoietic stem-cell transplantation: A pilot study
por: Ruan, Yongsheng, et al.
Publicado: (2023)

P1611: EFFICACY AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA IN A CHINESE ADULT POPULATION：A MULTICENTER, RANDOMIZED PHASE III TRIAL
por: Mei, Heng, et al.
Publicado: (2023)

Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy
por: Maitland, Hillary S.
Publicado: (2021)

Efficacy and Safety of Avatrombopag in Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Li, Chunlu, et al.
Publicado: (2019)

Case Report: Successful Avatrombopag Treatment for Two Cases of Anti-PD-1 Antibody-Induced Acquired Amegakaryocytic Thrombocytopenia
por: Tu, Xiaofang, et al.
Publicado: (2022)

Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial
por: Cui, Yayun, et al.
Publicado: (2022)

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumor s and hematologic malignancies
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia
por: Lambert, Michele P
Publicado: (2016)

Thrombocytopenia in Chronic Liver Disease: Challenges and Treatment Strategies
por: Desai, Shreya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7c40sne9qa7d57hl0u9fvr25hh